Sigfox and INDIGO® weel Join Forces to Promote 100% Connected Urban Mobility
12.7.2019 14:47:00 EEST | Business Wire | Press release
Self-service bicycle fleet INDIGO® weel, a subsidiary of the INDIGO group, has been fitted with sensors, supported by Sigfox's 0G network, that can accurately pinpoint their location at any given time. As the number of shared vehicles in circulation increases, this integration of Sigfox technology will help to better protect the fleet from damage or theft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190712005234/en/
Photo : INDIGO weel
The Sigfox solution offers multiple benefits for INDIGO® weel:
- An easier customer journey: pinpointing the location of bicycles more accurately, in real-time, allows users of the service to locate bikes on the street faster and more easily;
- Better protection against damage and theft due to a greater understanding of high-risk areas;
- A reduction in repair costs thanks to reusable sensors that can easily be transferred from a damaged bike to a new one;
- Flexible technology that can be used in other markets, if the INDIGO® weel service expands internationally, courtesy of Sigfox's global 0G network that spans some sixty countries;
- Durable sensors that consume very little energy
Together, INDIGO® weel and Sigfox are providing a solution to the public that addresses a number of the current challenges facing mobility services. Population growth in cities, as well as increasing environmental awareness now requires us to reconsider the way we move around each day. Innovative private sector services are therefore needed, in order to be able to offer a wider range of mobility solutions to the public. These must, however, complement the existing public transport offering, with those in charge working closely with city authorities in metropolitan areas.
New mobility solutions have been changing the face of city centre travel in recent years, but in order to be fully effective, they still have to find their place in the landscape. In this new market, INDIGO® weel is positioning itself as an innovative brand, keen to constantly evolve and partner with other forward-thinking businesses to do that.
One example of this innovation prompts users to take a photo at the end of their bike rental period to certify that the vehicle is in good parking condition. Each photo is then processed by customer services and users who comply with national, local and ‘Our Service’ rules will gain access to more advantageous offers.
Any change involves some risks and challenges, but the association between Sigfox and INDIGO® weel is already reaping benefits. Since the fleet was equipped with connected sensors, improvements to the geolocation system has reduced bicycle damage by a factor of 4. In addition, bicycle repair/replacement is now also faster than in the past. These improvements benefit INDIGO® weel, but also, more broadly, the inhabitants of cities where the connected vehicles are available, providing them with a high quality, sustainable service.
Jean Gadrat, CEO of INDIGO® weel, explains: "Public stakeholders and users today want a wider range of mobility solutions at their disposal and innovation in the sector that will help shape the city of tomorrow. It is in this context that we enter the market as a private company, in order to provide citizens with a respectful, complementary offering. INDIGO® weel wants to be a responsible player in the urban mobility market. We work tirelessly to offer the best possible service to our customers and make our products more efficient, which is why we have chosen to embed Sigfox’s technology into the fleet. It allows us to strengthen the sustainability of our offering and fully integrate our vehicles into the urban ecosystem.”
Patrick Cason, General Manager at Sigfox France, said: "Through this collaboration, we are once again demonstrating the many ways in which our 0G network can be used to serve society. The challenges of mobility, especially in cities, are many and well known. Faced with increasingly populated cities and an environmental awareness that can no longer be ignored, we must create new, more sustainable mobility solutions. Free floating bike is one of them. We are working with INDIGO® weel to provide the best service possible to meet the needs of citizens and to ensure that free floating bike finds its place in the city.”
About Sigfox
Sigfox is the initiator of the 0G network and the world’s leading IoT (Internet of Things) service provider. Its global network allows billions of devices to connect to the Internet, in a straightforward way, while consuming as little energy as possible. Sigfox unique approach to device-to-cloud communications addresses the three greatest barriers to global IoT adoption: cost, energy consumption and global scalability.
Today, the network is available in 60 countries, with 1 billion people covered. ISO 9001 certified and surrounded by a large ecosystem of partners and IoT key players, Sigfox empowers companies to move their business model towards more digital services, in key areas such as Asset Tracking and Supply Chain. Founded in 2010 by Ludovic Le Moan and Christophe Fourtet, the company is headquartered in France and has offices in Madrid, Munich, Boston, Dallas, San Jose, Dubai, Singapore, Sao Paulo and Tokyo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190712005234/en/
Contact information
Press:
Sigfox
Antoine Mège, PR & Content Manager
antoine.mege@sigfox.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
